Downregulated expression of miR-155, miR-17, and miR-181b, and upregulated expression of activation-induced cytidine deaminase and interferon-α in PBMCs from patients with SLE

References

• Crispín JC, Liossis SN, Kis-Toth K, Lieberman LA, Kyttaris VC, Juang YT, et al. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol Med. 2010;16(2):47–57.
   PubMed Web of Science ®Google Scholar
• Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med. 2008;358(9):929–39.
   PubMed Web of Science ®Google Scholar
• Mackay F, Schneider P, Rennert P, Browning J. BAFF and APRIL: a tutorial on B cell survival. Annu Rev Immunol. 2003;21:231–64.
   PubMed Web of Science ®Google Scholar
• Carroll MC. A protective role for innate immunity in systemic lupus erythematosus. Nat Rev Immunol. 2004;4(10):825–31.
   PubMed Web of Science ®Google Scholar
• McGaha TL, Sorrentino B, Ravetch JV. Restoration of tolerance in lupus by targeted inhibitory receptor expression. Science. 2005; 307(5709):590–3.
   PubMed Web of Science ®Google Scholar
• Koutouzov S, Mathian A, Dalloul A. Type-I interferons and systemic lupus erythematosus. Autoimmun Rev. 2006;5(8):554–62.
   PubMed Web of Science ®Google Scholar
• Pascual V, Farkas L, Banchereau J. Systemic lupus erythematosus: all roads lead to type I interferons. Curr Opin Immunol. 2006;18(6):676–82.
   PubMed Web of Science ®Google Scholar
• Christensen SR, Shlomchik MJ. Regulation of lupus-related autoantibody production and clinical disease by Toll-like receptors. Semin Immunol. 2007;19(1):11–23.
   PubMed Web of Science ®Google Scholar
• Komatsuda A, Wakui H, Iwamoto K, Ozawa M, Togashi M, Masai R, et al. Up-regulated expression of Toll-like receptors mRNAs in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Clin Exp Immunol. 2008;152(3):482–7.
   PubMed Web of Science ®Google Scholar
• Pauley KM, Cha S, Chan EK. MicroRNA in autoimmunity and autoimmune diseases. J Autoimmun. 2009;32(3–4):189–94.
   PubMed Web of Science ®Google Scholar
• Dai Y, Huang YS, Tang M, Lv TY, Hu CX, Tan YH, et al. Microarray analysis of microRNA expression in peripheral blood cells of systemic lupus erythematosus patients. Lupus. 2007;16(12):939–46.
   PubMed Web of Science ®Google Scholar
• Pauley KM, Satoh M, Chan AL, Bubb MR, Reeves WH, Chan EK. Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Res Ther. 2008; 10(4):R101.
   PubMed Web of Science ®Google Scholar
• Dai Y, Sui W, Lan H, Yan Q, Huang H, Huang Y. Comprehensive analysis of microRNA expression patterns in renal biopsies of lupus nephritis patients. Rheumatol Int. 2009;29(7):749–54.
   PubMed Web of Science ®Google Scholar
• Tang Y, Luo X, Cui H, Ni X, Yuan M, Guo Y, et al. MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum. 2009;60(4):1065–75.
   PubMed Web of Science ®Google Scholar
• Vinuesa CG, Rigby RJ, Yu D. Logic and extent of miRNA-mediated control of autoimmune gene expression. Int Rev Immunol. 2009; 28(3–4):112–38.
   PubMed Web of Science ®Google Scholar
• Tsitsiou E, Lindsay MA. MicroRNAs and the immune response. Curr Opin Pharmacol. 2009;9(4):514–20.
   PubMed Web of Science ®Google Scholar
• Baltimore D, Boldin MP, O’Connell RM, Rao DS, Taganov KD. MicroRNAs: new regulators of immune cell development and function. Nat Immunol. 2008;9(8):839–45.
   PubMed Web of Science ®Google Scholar
• Tan LP, Wang M, Robertus JL, Schakel RN, Gibcus JH, Diepstra A, et al. miRNA profiling of B-cell subsets: specific miRNA profile for germinal center B cells with variation between centroblasts and centrocytes. Lab Invest. 2009;89(6):708–16.
   PubMed Web of Science ®Google Scholar
• Incorvaia E, Sicouri L, Petersen-Mahrt SK, Schmitz KM. Hormones and AID: balancing immunity and autoimmunity. Autoimmunity. 2013;46(2):128–37.
   PubMed Web of Science ®Google Scholar
• Teng G, Hakimpour P, Landgraf P, Rice A, Tuschl T, Casellas R, Papavasiliou FN. MicroRNA-155 is a negative regulator of activation-induced cytidine deaminase. Immunity. 2008;28(5):621–9.
   PubMed Web of Science ®Google Scholar
• de Yébenes VG, Belver L, Pisano DG, González S, Villasante A, Croce C, et al. miR-181b negatively regulates activation-induced cytidine deaminase in B cells. J Exp Med. 2008;205(10):2199–206.
   PubMed Web of Science ®Google Scholar
• Wang P, Hou J, Lin L, Wang C, Liu X, Li D, et al. Inducible microRNA-155 feedback promotes type I IFN signaling in antiviral innate immunity by targeting suppressor of cytokine signaling 1. J Immunol. 2010;185(10):6226–33.
   PubMed Web of Science ®Google Scholar
• Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25(11):1271–7.
   PubMed Web of Science ®Google Scholar
• Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725 (letter).
   PubMed Web of Science ®Google Scholar
• Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. a disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992;35(6):630–40.
   PubMed Web of Science ®Google Scholar
• Yamanaka Y, Tagawa H, Takahashi N, Watanabe A, Guo YM, Iwamoto K, et al. Aberrant overexpression of microRNAs activate AKT signaling via down-regulation of tumor suppressors in natural killer-cell lymphoma/leukemia. Blood. 2009;114(15):3265–75.
   PubMed Web of Science ®Google Scholar
• Ronnblom LE, Alm GV, Oberg KE. Possible induction of systemic lupus erythematosus by interferon-α treatment in a patient with a malignant carcinoid tumour. J Intern Med. 1990;227(3):207–10.
   PubMed Web of Science ®Google Scholar
• Gota C, Calabrese L. Induction of clinical autoimmune disease by therapeutic interferon-α. Autoimmunity. 2003;36(8):511–8.
   PubMed Web of Science ®Google Scholar
• Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA. 2003;100(5):2610–5.
   PubMed Web of Science ®Google Scholar
• Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med. 2003;197(6):711–23.
   PubMed Web of Science ®Google Scholar
• Jiang C, Zhao ML, Diaz M. Activation-induced deaminase heterozygous MRL/lpr mice are delayed in the production of high-affinity pathogenic antibodies and in the development of lupus nephritis. Immunology. 2009;126(1):102–13.
   PubMed Web of Science ®Google Scholar
• Jiang C, Foley J, Clayton N, Kissling G, Jokinen M, Herbert R, Diaz M. Abrogation of lupus nephritis in activation-induced deaminase-deficient MRL/lpr mice. J Immunol. 2007;178(11):7422–31.
   PubMed Web of Science ®Google Scholar
• Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell. 2010;39(4):493–506.
   PubMed Web of Science ®Google Scholar
• Mansueto G, Forzati F, Ferraro A, Pallante P, Bianco M, Esposito F, et al. Identification of a new pathway for tumor progression: MicroRNA-181b up-regulation and CBX7 down-regulation by HMGA1 protein. Genes Cancer. 2010;1(3):210–24.
   PubMedGoogle Scholar
• Liu J, Shi W, Wu C, Ju J, Jiang J. miR181b as a key regulator of the oncogenic process and its clinical implications in cancer (Review). Biomedical Reports. 2014;2(1):7–11.
   PubMedGoogle Scholar
• Huang X, Guo Y, Bao C, Shen CN. Multidimensional single cell based STAT phosphorylation profiling identifies a novel biosignature for evaluation of systemic lupus erythematosus activity. PLoS One. 2011;6(7):e21671.
   PubMed Web of Science ®Google Scholar
• Klinge CM. miRNAs and estrogen action. Trends Endocrinol Metab. 2012;23(5):223–33.
   PubMed Web of Science ®Google Scholar